ENDPOINTS

#ASCO25: Strand Therapeutics reports promising start for mRNA cancer therapy

A Boston biotech with self-replicating mRNA technology has shared early data from its lead candidate for cancers that are refractory to immune checkpoint inhibitors. Strand Therapeutics said on Wednesday that STX-001 showed initial signs of ...

May 28, 2025 - 12:04
 0
#ASCO25: Strand Therapeutics reports promising start for mRNA cancer therapy
A Boston biotech with self-replicating mRNA technology has shared early data from its lead candidate for cancers that are refractory to immune checkpoint inhibitors. Strand Therapeutics said on Wednesday that STX-001 showed initial signs of ...
Read More

Tags:

Previous Article

Develop valuable data visualization skills and learn to code for only $50

Next Article

MD Anderson targets $250M for second cancer biotech fund

Related Posts

Trump unofficially taps CMS chief Oz to spearhead 'most favored nation' talks

Trump unofficially taps CMS chief Oz to spearhead 'most...

May 23, 2025  0

FDA asks Covid vaccine makers to add more myocarditis data to labels

FDA asks Covid vaccine makers to add more myocarditis d...

May 21, 2025  0

Reproductive health biotech ReproNovo closes $65M Series A

Reproductive health biotech ReproNovo closes $65M Series A

May 21, 2025  0